NCT05463861View on ClinicalTrials.gov

Lemborexant in Delayed Sleep Phase Syndrome

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Delayed Sleep Phase Syndrome
Interventions
DRUG

Lemborexant

Lemborexant tablet administered orally once daily.

DRUG

Placebo

Placebo to match Lemborexant tablet administered orally once daily.

Trial Locations (1)

94063

RECRUITING

Stanford Univeristy, Redwood City

All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

lead

Stanford University

OTHER

NCT05463861 - Lemborexant in Delayed Sleep Phase Syndrome | Biotech Hunter | Biotech Hunter